Looking forward to that increased News Flow Gary promoted at the...

  1. 13,513 Posts.
    lightbulb Created with Sketch. 7311
    Looking forward to that increased News Flow Gary promoted at the July presentation.

    I'm happy to sit and wait here , sometimes you just have to stand still and wait for the Money/ Demand to come to you..

    I'll be here until the SNT 6302 Trial is completed ... every single factor surrounding SNT 6302 has been positive to date ,, me I would have it as the lead candidate to ramp up the SP as its a highly visual easily understood dermal treatment.

    Dermal application being the lowest on the Complexity matrix well under Ingestion, Intravenous , Implant.

    Burns and Scarring are highly visual with simple before and after shots,, Dr Fiona Woods doesn't make statements lightly not many topline PHD's + Surgeons rarely make statements at all.. Certainly when I hear words "Unprecedented Change"

    “This exploratory clinical study has significantly enhanced our understanding of the role of LOX enzymes in scarring and the scar process itself. PXS-6302 safely inhibits these key enzymes to a significant degree and leads directly to an unprecedented change to the scar composition that we have not seen with any other form of treatment".

    https://www.linkedin.com/posts/gary-phillips-838590_professor-fiona-wood-am-leading-pxs-6302-activity-6950678095397814272-Hm5S/

    Chanel 9 News
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
5.1¢
Change
0.000(0.00%)
Mkt cap ! $82.87M
Open High Low Value Volume
5.1¢ 5.4¢ 5.1¢ $107.2K 2.071M

Buyers (Bids)

No. Vol. Price($)
2 534937 5.1¢
 

Sellers (Offers)

Price($) Vol. No.
5.3¢ 18846 1
View Market Depth
Last trade - 16.10pm 27/06/2025 (20 minute delay) ?
SNT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.